Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
LLY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$677.09 - $972.53
Previous CloseN/A
Volume1.27M
Average Volume (3M)3.74M
Market Cap
$683.41B
Enterprise Value$761.80B
Total Cash (Recent Filing)$4.73B
Total Debt (Recent Filing)$6.68B
Price to Earnings (P/E)61.5
Beta0.73
Next Earnings
May 01, 2025EPS Estimate
4.66Last Dividend Ex-Date
Feb 14, 2025Dividend Yield0.75%
Share Statistics
EPS (TTM)11.49
Shares Outstanding947,989,140
10 Day Avg. Volume4,067,366
30 Day Avg. Volume3,740,965
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)N/A
Price to Sales (P/S)17.63
Price to Cash Flow (P/CF)80.30
P/FCF Ratio203.10
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit20.80
Enterprise Value/Ebitda48.75
Forecast
1Y Price Target
$1,038.21Price Target Upside41.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Global ExpansionThe launch of tirzepatide in India at a competitive price could significantly boost Eli Lilly's sales outside the US.
Market PositionEli Lilly & Co. is seen as maintaining its leading position in a market expected to triple in size, driven by its anti-obesity medication market model.
Product PotentialThe company is projected to achieve significant commercial potential for its once-daily oral small molecule, orforglipron, with global launches and strong sales forecasts.
Bears Say
Medicare CoverageHHS’s decision to not finalize provisions that would have provided coverage for anti-obesity medications such as Lilly’s tirzepatide did not come as a surprise given RFKJ’s past comments and the politicized nature of policies.
Tariffs ImpactEli Lilly's CEO stated that the company might have to absorb the cost of tariffs, potentially leading to trade-offs within the company, such as staff reductions.
---
Ownership Overview
10.30% Insiders
22.41% Mutual Funds
27.73% Other Institutional Investors
22.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was $677.09 and its highest was $972.53 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Eli Lilly & Co’s market cap is $683.41B.
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is May 01, 2025 which is in 18 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Feb 06, 2025. The company reported $5.32 earnings per share for the quarter, beating the consensus estimate of $5.045 by $0.275.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of $1.5 which represents an annual dividend yield of 0.75%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is 4.66.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 947,989,140 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of $5.32 in its last earnings report, beating expectations of $5.045. Following the earnings report the stock price went up 3.347%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Currently, no hedge funds are holding shares in LLY
---
Eli Lilly & Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,038.21 (41.75% Upside)
$1,038.21 (41.75% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 84%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 644.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2B over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.95%
12-Months-Change
Fundamentals
Return on Equity
84.84%
Trailing 12-Months
Asset Growth
22.98%
Trailing 12-Months
Company Description
Eli Lilly & Co
Eli Lilly & Co (LLY) is a global pharmaceutical company that discovers, develops, manufactures, and markets products in human health. The company focuses on several key therapeutic areas, including diabetes, oncology, immunology, neurodegeneration, and pain management. With a robust portfolio of innovative medicines, Eli Lilly aims to improve patient outcomes and address unmet medical needs worldwide.
---
LLY Company Deck
---
LLY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and successful product launches, underpinned by strategic investments and advancements in the pipeline. However, challenges such as pricing pressures, a decline in Trulicity revenue, and supply constraints in certain regions tempered the overall positive outlook.Read More>---
LLY Revenue Breakdown
67.44% U.S.
15.36% Europe
9.48% ROW
4.03% Japan
3.69% China
---
LLY Stock 12 Month Forecast
Average Price Target
$1,038.21
▲(41.75% Upside)
Technical Analysis
Best Analysts Covering LLY
1 Year
1 Year Success Rate
29/36 ratings generated profit
1 Year Average Return
+35.36%
reiterated a buy rating 2 months ago
Copying Chris Schott's trades and holding each position for 1 Year would result in 80.56% of your transactions generating a profit, with an average return of +35.36% per trade.
---